Mandate

Vinge advises Santander Consumer Finance in connection with its acquisition of Athlon Sweden AB

Vinge advises Santander Consumer Finance in connection with its acquisition of all shares in Athlon Sweden AB, which is part of Mercedes-Benz Mobility.

Athlon Sweden AB, operating in the field of car leasing and fleet management, is headquartered in Malmö, with a sales presence also in Stockholm. The company has demonstrated substantial growth over the last five years and currently manages a portfolio of 5,200 cars and vans, positioning itself as the ninth-largest player in the Swedish market.

The completion of the transaction is subject to customary regulatory approvals.

Vinge´s team consisted of Christina Kokko together with Isabelle Wållgren, Robin Fagerström (M&A), Christoffer Nordin, Sam Fakhraie Ardekani (Commercial Agreements), Lisa Hörnqvist (GDPR/IT), Emma-Stuart Beck, Caroline Krassén, Elias Bohlin (Financial Services), David Flodin (Banking and Finance), Jonna Bondemark (Insurance Regulatory), Axel Lennartsson (IPR), Madelene Andersson (Real Estate), Gulestan Ali (Employment), Fanny Askelöf (Transaction Support Specialist), and Emma Emsjö (Project Assistant).

Related

Vinge advises OsteoCentric on the public offer for Integrum

OsteoCentric Oncology and Bone Anchored Prostheses, LLC, a subsidiary of OsteoCentric Technologies, Inc., has made a public offer for all shares in Integrum AB (publ). The offer values all shares in Integrum at approximately SEK 939 million.
July 23, 2025

Vinge advises Investor on its co-investment in the SEK 55 billion public offer for Fortnox led by EQT X

Vinge advises Investor AB (publ) (“Investor”) on its co-investment in the public offer for Fortnox AB (publ) (“Fortnox”) led by EQT X together with First Kraft AB (owned by Olof Hallrup), acting through Omega II AB (“Omega II”). Fortnox offers vital software infrastructure to small and medium-sized companies in Sweden with a track record of profitable growth.
July 22, 2025

Vinge advises Cantargia in connection with the sale of immunology program CAN10

Vinge advises Cantargia AB (publ) in connection with the sale of its early-clinical stage IL1RAP immunology program CAN10 to the Japanese healthcare company Otsuka Pharmaceutical.
July 21, 2025